Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

101. Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines

Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness (...) and Guidelines Published on: May 4, 2016 Project Number: RB0983-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question 1. What is the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? 2. What are the evidence-based guidelines associated with delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? Key Message Three systematic

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

102. Modifiable Risk Factors in the Progression of Multiple Sclerosis

Modifiable Risk Factors in the Progression of Multiple Sclerosis Management Briefs Search the HSR&D website Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Brief no. 111 » Issue 111 April 2016 The systematic review reported on here is a product of the VA/HSR&D Quality Enhancement Research Initiative (QUERI) Evidence-Based Synthesis Program. Systematic (...) Review: Modifiable Risk Factors in the Progression of Multiple Sclerosis Multiple sclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the cause of serious physical disability in adults of working age. MS disease presentation is very heterogeneous with variable clinical manifestations that evolve over time. In about 50 percent of patients the course of MS changes from relapsing-remitting to secondary progressive disease after ten years. Relapsing

Veterans Affairs - R&D2016

103. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.

Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27074083 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Apr 14;374(15):1495-6. doi: 10.1056/NEJMc1513302. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. 1 , 1 , 1 . 1 Yale School of Medicine, New Haven, CT kevin.oconnor@yale.edu. PMID: 27074083 PMCID: DOI: [Indexed for MEDLINE] Images from this publication. Figure 1 Detection of KIR4.1

NEJM2016 Full Text: Link to full Text with Trip Pro

104. Multiple Sclerosis and Antibodies against KIR4.1.

Multiple Sclerosis and Antibodies against KIR4.1. Multiple Sclerosis and Antibodies against KIR4.1. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27074084 Format MeSH and Other Data E-mail Subject Additional (...) text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131. Multiple Sclerosis and Antibodies against KIR4.1. 1 , 1 , 1 , 1 , 1 , 1 , 1 . 1 University Hospital Basel, Basel, Switzerland tobias.derfuss@usb.ch. PMID: 27074084 DOI: [Indexed for MEDLINE] Free full text Publication type MeSH terms Substances Full Text Sources Medical PubMed

NEJM2016

105. Teriflunomide for multiple sclerosis.

Teriflunomide for multiple sclerosis. BACKGROUND: This is an update of the Cochrane review "Teriflunomide for multiple sclerosis" (first published in The Cochrane Library 2012, Issue 12).Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system. It is clinically characterized by recurrent relapses or progression, or both, often leading to severe neurological disability and a serious decline in quality of life. Disease-modifying therapies (DMTs) for MS aim (...) to prevent occurrence of relapses and disability progression. Teriflunomide is a pyrimidine synthesis inhibitor approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a DMT for adults with relapsing-remitting MS (RRMS). OBJECTIVES: To assess the absolute and comparative effectiveness and safety of teriflunomide as monotherapy or combination therapy versus placebo or other disease-modifying drugs (DMDs) (interferon beta (IFNβ), glatiramer acetate, natalizumab

Cochrane2016

106. Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness

Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness Published on: March 10, 2016 Project (...) Number: RC0755-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of vitamin D supplementation for the prevention of multiple sclerosis? What is the clinical effectiveness of high versus low dose vitamin D supplementation for the prevention of multiple sclerosis? What is the clinical effectiveness of vitamin D supplementation for the treatment of multiple sclerosis? What is the clinical effectiveness

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

107. Medicines used for Multiple Sclerosis A Health Technology Assessment

Medicines used for Multiple Sclerosis A Health Technology Assessment Medicines used for Multiple Sclerosis A Health Technology Assessment - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Rapport fra Folkehelseinstituttet - Fullstendig metodevurdering Medicines used for Multiple Sclerosis A Health Technology Assessment (...) Published 29/02/2016 Changed 07/03/2016 Couto E, Hamidi V, Ringerike T, Odgaard-Jensen J, Harboe I, Klemp M. Medicines used for Multiple Sclerosis A Health Technology Assessment. Rapport fra Folkehelseinstituttet – 2016. ISBN 978-82-8082-706-7 Key messages This Health Technology Assessment was commissioned by the “National system for the introduction of new health technologies within the specialist health service”. The aim of this report was to assess the effect and cost-effectiveness of the disease

The Norwegian Knowledge Centre for the Health Services2016

108. Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.

Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis. CLINICAL QUESTION: What immunotherapies for multiple sclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiple sclerosis? BOTTOM LINE: Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening

JAMA2016

109. Multiple sclerosis following a spinal cord injury: a rare and unfortunate case

Multiple sclerosis following a spinal cord injury: a rare and unfortunate case 28053730 2018 11 13 2058-6124 2 2016 Spinal cord series and cases Spinal Cord Ser Cases Multiple sclerosis following a spinal cord injury: a rare and unfortunate case. 15027 10.1038/scsandc.2015.27 This is a case report and review of literature with the objective report of the case of a young man with physical disability following a traumatic spinal cord injury (SCI) who was later newly diagnosed (...) with multiple sclerosis (MS) in an inpatient SCI rehabilitation center. (Barcelona, Spain). A 24-year-old male sustained a traumatic spinal cord lesion (T9 AIS A) as the result of a motorcycle accident. He completed his rehabilitation process without complications and returned to the community having adjusted to his new disability. Two and a half years after his initial injury, he attended the clinic after experiencing 2 months of paresthesias in his left hand, progressing to his right upper limb, and difficulty

Spinal cord series and cases2016 Full Text: Link to full Text with Trip Pro

110. Medicines used for Multiple Sclerosis A Health

Medicines used for Multiple Sclerosis A Health Medicines used for Multiple Sclerosis A Health - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Medicines used for Multiple Sclerosis A Health Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality and Knowledge Close More topics Close This Health Technology Assessment (...) was commissioned by the “National system for the introduction of new health technologies within the specialist health service”. The aim of this report was to assess the effect and cost-effectiveness of the disease modifying medicines used in Norway for patients with relapsing remitting multiple sclerosis (dimethyl fumarate, teriflunomide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fingolimod, and alemtuzumab). The key results are: • We identified 37 randomised clinical trials

Norwegian Institute of Public Health2016

111. The Use of Kinect to Improve Balance and Postural Control in Patients with Multiple Sclerosis

The Use of Kinect to Improve Balance and Postural Control in Patients with Multiple Sclerosis "The Use of Kinect to Improve Balance and Postural Control in Patients " by Theresa R. Jones < > > > > > Title Author Date of Award Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen Second Advisor Annjanette Sommers Rights . Abstract Background: Multiple sclerosis (MS) is a leading cause of disability in young (...) adults, affecting women more than men. Many MS patients experience gait difficulties due to muscle weakness and loss of balance and postural control. Standard interventions for maintaining or improving balance are addressed with conventional physical therapy, but this is often costly, time-consuming, and geographically inaccessible, all of which impact patient compliance. The primary goal of this systematic literature review investigates and addresses whether virtual reality therapy using Xbox Kinect

Pacific University EBM Capstone Project2016

112. The Use of Amphetamines for Improving Cognitive Impairment in Patients with Multiple Sclerosis

The Use of Amphetamines for Improving Cognitive Impairment in Patients with Multiple Sclerosis "The Use of Amphetamines for Improving Cognitive Impairment in Patients" by Hayley Kum < > > > > > Title Author Date of Award Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Elizabeth Crawford, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Multiple sclerosis (MS) is an autoimmune disorder (...) that results in debilitating cognitive impairment in 40-65% of patients. There are no current treatments for this symptom of MS. This is a systematic review of literature on the impact amphetamines have on cognitive function of MS patients. Methods: An exhaustive search of available medical literature was conducted using MEDLINE-Ovid, MEDLINE-PubMed, Web of Science, and CINAHL. Keywords used included: amphetamines and multiple sclerosis. Relevant articles were assessed for quality using GRADE. Results

Pacific University EBM Capstone Project2016

113. Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients

Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) .. Functional Electrical Stimulation (FES) for treatment of foot drop in multiple sclerosis patients. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Electric Stimulation; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Peroneal Neuropathies Language Published English Country of organisation United States English summary An English language summary is available. Address

Health Technology Assessment (HTA) Database.2015

114. Autologous hematopoietic stemcell transplantation for Multiple Sclerosis

Autologous hematopoietic stemcell transplantation for Multiple Sclerosis Autologous hematopoietic stemcell transplantation for Multiple Sclerosis - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Rapport fra Kunnskapssenteret - Fullstendig metodevurdering Autologous hematopoietic stemcell transplantation for Multiple Sclerosis (...) Published 25/11/2015 Changed 30/11/2015 Giske L, Lauvrak V, Stoinska-Schneider A, Frønsdal K, Kvamme MK., Ormstad S, Fure B. Autologous hematopoietic stemcell transplantation for Multiple Sclerosis. Rapport fra Kunnskapssenteret nr. 23 – 2015. ISBN 978-82-8121-992-2 ISSN 1890-1298 . Key messages Autologous hematopoietic stem cell transplantation is a treatment that has been suggested for a small group of patients with relapsing remitting multiple sclerosis where available medication has limited effect

The Norwegian Knowledge Centre for the Health Services2015

115. Glatiramer acetate (Copaxane) - treatment of relapsing forms of multiple sclerosis (MS).

Glatiramer acetate (Copaxane) - treatment of relapsing forms of multiple sclerosis (MS). Published 07 December 2015 Product Update glatiramer acetate 40mg/mL solution for injection prefilled syringes (Copaxone ® ) SMC No. (1108/15) Teva UK Limited 06 November 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission glatiramer acetate 40mg/mL (Copaxone ® ) is accepted for use within NHS Scotland. Indication under review: treatment of relapsing forms of multiple sclerosis (MS). This new formulation of glatiramer acetate (40mg/ml) given three times a week costs the same as the currently available formulation (glatiramer acetate 20mg/ml) that is given daily. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice

Scottish Medicines Consortium2015

116. Sodium channel blockers for neuroprotection in multiple sclerosis.

Sodium channel blockers for neuroprotection in multiple sclerosis. BACKGROUND: Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating disease of the central nervous system (CNS), which can occur in many parts of the CNS and result in a wide range of symptoms including sensory impairment, fatigue, walking or balance problems, visual impairment, vertigo and cognitive disabilities. At present, the most commonly used MS treatments are immunomodulating agents, but they have little (...) effect on the disability. Experimental studies show that sodium (Na(+)) accumulation leads to intracellular calcium (Ca(2+)) release, and the increased calcium levels can activate nitric oxide synthase and harmful proteases and lipases. These factors contribute to axonal injury in people with MS. If partial blockade of voltage-gated sodium channels could result in neuroprotection, this would be of benefit for preventing disability progression in these people. Neuroprotection is emerging

Cochrane2015

117. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. 26444729 2015 10 08 2015 10 15 2015 11 19 1533-4406 373 15 2015 Oct 08 The New England journal of medicine N. Engl. J. Med. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. 1418-28 10.1056/NEJMoa1501481 Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities (...) in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders. We conducted a randomized, double-blind, active-controlled, phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP, administered subcutaneously at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a dose of 30 μg once weekly, for up to 144 weeks. The primary end point was the annualized relapse

NEJM2015

118. Peginterferon beta-1a (Plegridy) - for the treatment of relapsing remitting multiple sclerosis

Peginterferon beta-1a (Plegridy) - for the treatment of relapsing remitting multiple sclerosis Final Appraisal Recommendation Advice No: 1615 – June 2015 Peginterferon beta-1a (Plegridy ® ? ) 63 micrograms, 94 micrograms and 125 micrograms solution for injection in pre-filled pen Submission by Biogen Idec Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2013), which includes the AWMSG Secretariat (...) in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1615: Peginterferon beta-1a (Plegridy ® ? ) 63 micrograms, 94 micrograms and 125 micrograms solution for injection in pre-filled pen. June 2015. Recommendation of AWMSG Peginterferon beta-1a (Plegridy ® ? ) is recommended as an option for use within NHS Wales in adult patients for the treatment of relapsing remitting multiple sclerosis.

All Wales Medicines Strategy Group2015

119. Guidelines for prescribing disease-modifying treatments in multiple sclerosis

Guidelines for prescribing disease-modifying treatments in multiple sclerosis Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis Neil Scolding, 1 David Barnes, 2 Sarah Cader, 3 Jeremy Chataway, 4 Abhijit Chaudhuri, 5 Alasdair Coles, 6 Gavin Giovannoni, 7 David Miller, 8 Waqar Rashid, 9 Klaus Schmierer, 10 Abdullah Shehu, 11 Eli Silber, 12 Carolyn Young, 13 John Zajicek 14 ? Additional material is published online (...) -001139 INTRODUCTION In June 1999, the Association of British Neurologists (ABN) first published guide- lines for the use of the licensed multiple sclerosis (MS) disease-modifying treat- ments (at that time ß-interferon and gla- tiramer acetate). The guidelines were revised in 2001 and have been periodic- ally updated since then. In 2002, follow- ing the negative assessment of these treatments by the National Institute for Health and Care Excellence (NICE), the MS risk-sharing scheme started, in which

Association of British Neurologists2015

120. Effect of comorbidity on mortality in multiple sclerosis

Effect of comorbidity on mortality in multiple sclerosis 26019190 2015 07 21 2015 10 16 2017 02 20 1526-632X 85 3 2015 Jul 21 Neurology Neurology Effect of comorbidity on mortality in multiple sclerosis. 240-7 10.1212/WNL.0000000000001718 We aimed to compare survival in the multiple sclerosis (MS) population with a matched cohort from the general population, and to evaluate the association of comorbidity with survival in both populations. Using population-based administrative data, we (...) identified 5,797 persons with MS and 28,807 controls matched on sex, year of birth, and region. We estimated annual mortality rates. Using Cox proportional hazards regression, we evaluated the association between comorbidity status and mortality, stratifying by birth cohort, and adjusting for sex, socioeconomic status, and region. We compared causes of death between populations. Median survival from birth in the MS population was 75.9 years vs 83.4 years in the matched population. MS was associated

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro